$46.26-3.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 12, 2026
Just reported
From Anaptysbio, Inc.'s results release of November 12, 2026; its quarterly report has since been filed.
Actual
$30.3M
-60% y/y
+10% q/q
Guided
—
No guide given
Actual
$0.11
-79% y/y
-98% q/q
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $30.3M | $76.3M | -60.33% |
| Profit | $3.9M | $15.1M | -74.35% |
| Profit per share | $0.11 | $0.52 | -78.85% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Anaptysbio, Inc. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Jemperli ’s continued commercial growth in endometrial cancer, with global net sales reaching $1 billion through September 30, 2026, and its recent U.S. approval in adults with stage II and III MSI-H/dMMR locally advanced rectal cancer reinforce our confidence in its long-term potential in monotherapy indications,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Anaptys manages the financial collaborations for Jemperli with GSK and Quimilza with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Anaptysbio, Inc.’s Item 2.02 8-K filed November 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Actual
$19.9M
-74% y/y
-70% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.